Fosamax (alendronate) will soon be promoted to PREVENT osteoporosis in postmenopausal women

    Fosamax (alendronate) will soon be promoted to PREVENT osteoporosis in postmenopausal women.

    It was originally approved just for treatment.

    Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote